Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Connect Bio Reports Positive Data from Phase II Trial of Dermatitis Therapy

publication date: Nov 19, 2021

Taicang Connect Bio reported that its interleukin-4 receptor alpha (IL-4Rα) candidate met its primary endpoint in a global Phase II trial for atopic dermatitis. The trial tested CBP-201 in three dosing arms, all of which showed statistically significant improvements of 50% to 75% eczema reduction compared to currently available therapies. Although the news was positive, Connect's stock price dropped 50% to $5.75. The company's stock price has now dropped 66% from the level of its March IPO, which was priced at $17 per share. More details....

Stock Symbol: (NSDQ: CNTB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital